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Reverse transcription-quantitative polymerase chain reac-
tion (RT-qPCR) assays, systems, methods and kits for the 
age determination of an individual from bloodstains or 
samples of unknown origin. The methodology is based on 
gene expression profiling analysis in which novel human 
newborn fetal specific genes are identified by detecting the 
presence of appropriate messenger RNA species. 
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HBGl 
acactcgcttctggaacgtctgaggttatcaataagctcctagtccagacgccatgggtcatttcacagaggaggacaaggctac 
tatcacaagcctgtggggcaaggtgaatgtggaagatgctggaggagaaaccctgggaaggctcctggttgtctacccatgga 
cccagaggttctttgacagctttggcaacctgtcctctgcctctgccatcatgggcaaccccaaagtcaaggcacatggcaagaa 
ggtgctgacttccttgggagatgccacaaagcacctggatgatctcaagggcacctttgcccagctgagtgaactgcactgtgac 
aagctgcatgtggatcctgagaacttcaagctcctgggaaatgtgctggtgaccgttttggcaatccatttcggcaaagaattcac 
ccctgaggtgcaggcttcctggcagaagatggtgactgcagtggccagtgccctgtcctccagataccactgagctcactgccc 
atgattcagagctttcaaggataggctttattctgcaagcaatacaaataataaatctattctgctgagagatcac 
Figure 1 
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HBG2 
acactcgcttctggaacgtctgaggttatcaataagctcctagtccagacgccatgggtcatttcacagaggaggacaaggctac 
tatcacaagcctgtggggcaaggtgaatgtggaagatgctggaggagaaaccctgggaaggctcctggttgtctacccatgga 
cccagaggttctttgacagctttggcaacctgtcctctgcctctgccatcatgggcaaccccaaagtcaaggcacatggcaagaa 
ggtgctgacttccttgggagatgccataaagcacctggatgatctcaagggcacctttgcccagctgagtgaactgcactgtgac 
aagctgcatgtggatcctgagaacttcaagctcctgggaaatgtgctggtgaccgttttggcaatccatttcggcaaagaattcac 
ccctgaggtgcaggcttcctggcagaagatggtgactggagtggccagtgccctgtcctccagataccactgagctcactgccc 
atgatgcagagctttcaaggataggctttattctgcaagcaatcaaataataaatctattctgctaagagatcac 
Figure 2 
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HBGln 
acactcgcttctggaacgtctgaggttatcaataagctcctagtccagacgccatgggtcatttcacagaggaggacaaggctac 
tatcacaagcctgtggggcaaggtgaatgtggaagatgctggaggagaaaccctgggaaggctcctggttgtctacccatgga 
cccagaggttctttgacagctttggcaacctgtcctctgcctctgccatcatgggcaaccccaaagtcaaggcacatggcaagaa 
ggtgctgacttccttgggagatgccacaaagcacctggatgattcagagctttcaaggataggctttattctgcaagcaatacaaat 
aataaatctattctgctgagagatcac 
Sequence ID 1 
Figure 3 
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HBG2n 
acactcgcttctggaacgtctgaggttatcaataagctcctagtccagacgccatgggtcamcacagaggaggacaaggctac 
tatcacaagcctgtggggcaaggtgaatgtggaagatgctggaggagaaaccctgggaaggctcctggttgtctacccatgga 
cccagaggttctttgacagctttggcaacctgtcctctgcctctgccatcatgggcaaccccaaagtcaaggcacatggcaagaa 
ggtgctgacttccttgggagatgccataaagcacctggatgatctcaagggcaccmgcccagctgagtgaactgcactgagct 
cactgcccatgatgcagagcmcaaggataggctttattctgcaagcaatcaaataataaatctattctgctaagagatcac 
Sequence ID 2 
Figure 4 
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SIS 
ggcagtctcgcgataactgcgcaggcgcggaccaaagcgatctcttctgaggatccggcaagatggcagaagtagagcagaa 
gaagaagcggaccttccgcaagttcacctaccgcggcgtggacctcgaccagctgctggacatgtcctacgagcagctgatgc 
agctgtacagtgcgcgccagcggcggcggctgaaccggggcctgcggcggaagcagcactccctgctgaagcgcctgcgc 
aaggccaagaaggaggcgccgcccatggagaagccggaagtggtgaagacgcacctgcgggacatgatcatcctacccga 
gatggtgggcagcatggtgggcgtctacaacggcaagaccttcaaccaggtggagatcaagcccgagatgatcggccactac 
ctgggcgagttctccatcacctacaagcccgtaaagcatggccggcccggcatcggggccacccactcctcccgcttcatccct 
ctcaagtaatggctcagctaataaaggcgcacatgactcc 
Sequence ID 3 
Figure 5 
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F 5' gaa-agc-tct-gaa-tca-tcc-agg-tg 3' 
Sequence ID 4 
US 7,276,340 Bl 
Figure 6 
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6FAM-ttt-gtg-gca-tct-ccc-aag-gaa-gtc-agc MGBNFQ 
Sequence ID 5 
Figure 7 
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R 5' agt-caa-ggc-aca-tgg-caa-gaa-g 3' 
Sequence ID 6 
Figure 8 
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F 5' gca-gtg-agc-tca-gtg-cag-ttc 3' 
Sequence ID 7 
Figure 9 
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6F AM-caa-agg-tgc-cct-tga-gat-cat-cca-gg MGBNFQ 
Sequence ID 8 
Figure 10 
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R 5' ttc-ctt-ggg-aga-tgc-cat-aaa 3' 
Sequence ID 9 
Figure 11 
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F 5' cca-aag-cga-tct-ctt-ctg-agg-at 3 
Sequence ID 10 
Figure 12 
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VIC-cgg-caa-gat-ggc-aga-agt-aga-gca-gaa MGBNFQ 
Sequence ID 11 
Figure 13 
U.S. Patent Oct. 2, 2007 Sheet 14 of 14 US 7,276,340 Bl 
R 5' acg-ccg-cgg-tag-gtg-aa 
Sequence ID 12 
Figure 14 
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1 
AGE DETERMINATION FROM 
BIOLOGICAL STAINS USING MESSENGER 
RNA PROFILING ANALYSIS 
This invention claims the benefit of priority from U.S. 
Provisional Application Ser. No. 60/612,233 filed Sep. 22, 
2004 the content of which is incorporated herein by refer-
ence. 
FIELD OF THE INVENTION 
This invention relates to a ribonucleic acid (RNA) based 
assay system for determining the biological age of an 
individual from which a body fluid originated. 
SEQUENCE LISTING 
Appendix A is a sequence listing of mRNA and DNA 
sequences identified in FIGS. 1-14, the content of Appendix 
2 
Numerous molecular theories have been investigated for 
their correlation with human ageing. Postulated molecular 
mechanisms include, inter alia, progressive damage to DNA, 
telomere shortening, long-lived protein glycation and reac-
5 tive oxygen species (ROS)-mediated oxidative damage to 
macromolecules. A major downfall to these approaches is 
that they are characterized by the "degenerative" ageing 
process, whereby as individuals increase in age the amount 
of damage also increases, this is especially characteristic of 
10 older aged individuals. From the forensic standpoint, how-
ever, it would be useful to be able to distinguish between 
individuals of all age groups and this may require the 
detection of more subtle molecular changes. An alternate 
approach to age determination relies on epigenetic and 
15 developmental control of gene expression through messen-
ger RNA (mRNA) profiling analysis. This theory of"devel-
opmental" ageing, would allow individuals to be categorized 
into various age groups, each correlated with a specific stage 
A is also submitted on a compact disc and is incorporated 20 
herein by reference. Attached hereto is one compact disc 
containing the following files: 
of human development. 
The life-cycle of humans comprises a number of devel-
opmentally recognized stages. As the human proceeds 
through these developmental stages, sub-sets of the 20-50 
thousand human genes will be differentially expressed. SEQ. 1 provides the mRNA sequence of HBGl 
SEQ. 2 provides the mRNA sequence of HBG2 
SEQ. 3 provides the mRNA sequence ofHBGln (Seq. ID 25 
1) 
Determining the global gene expression profile (or differ-
ential mRNA gene expression profile) present in a biological 
stain could reveal constellations of genes whose expression 
is correlated with a specific age. For example, identifying 
fetal hemoglobin (HBG) and fetal specific regulating mRNA 
SEQ. 4 provides the mRNA sequence ofHBG2n (Seq. ID 
2) 
SEQ. 5 provides the mRNA sequence of S15 (Seq. ID 3) 
SEQ. 6 provides the DNA sequence of an HBG ln primer 30 
(Seq. ID 4) 
species, isolating pubertal and pre-pubertal hormones and 
receptors or assaying for DNA damage and repair factors 
would be indicative of newborn babies, adolescent teenagers 
and elderly individuals, respectively. SEQ. 7 provides the DNA sequences of an HBG ln probe (Seq. ID 5) 
SEQ. 8 provides the DNA sequences of an HBG ln primer 
(Seq. ID 6) 
SEQ. 9 provides the DNA sequences of an HBG2n primer 
(Seq. ID 7) 
SEQ. 10 provides the DNA sequences of an HBG2n probe 
(Seq. ID 8) 
SEQ. 11 provides the DNA sequences of an HBG2n 
primer (Seq. ID 9) 
SEQ. 12 provides the DNA sequences of an S15 primer 
(Seq. ID 10) 
SEQ. 13 provides the DNA sequences of an S15 probe 
(Seq. ID 11) 
SEQ. 14 provides the DNA sequences of an S15 primer 
(Seq. ID 12) 
BACKGROUND AND PRIOR ART 
It is now a routine matter for forensic scientists to obtain 
the genetic profile of an individual from deoxyribonucleic 
acid (DNA) recovered from a biological stain deposited at a 
crime scene. However, in certain instances where there is no 
developed suspect as yet or there is no match with any 
database sample, the DNA profile per se provides no mean-
ingful information to investigators, with the notable excep-
tion of gender determination. To aid in these investigations 
another useful biometric that could provide important pro-
bative information is the biological age of an individual. For 
example, the ability to provide investigators with informa-
tion as to whether a DNA donor is a newborn baby, an 
adolescent teenager or an elderly individual could be useful 
35 
SUMMARY OF THE INVENTION 
A primary objective of the present invention is to provide 
two novel newborn specific fetal hemoglobin genes. 
A second objective of the present invention is to provide 
40 
an mRNA based method for identifying the newborn specific 
genes present in a bloodstain. 
45 
A third objective of the present invention is to provide a 
kit for the analysis of bloodstains to determine if a particular 
bloodstain originated from a newborn individual. 
A preferred method for identifying whether a stain con-
tains blood of a newborn human being, includes, obtaining 
a sample stain consisting of a body fluid from a human 
being, extracting total ribonucleic acid (tRNA) from the 
sample stain, treating the total RNA with an enzyme, initi-
50 ating a reverse-transcription (RT) reaction by treating total 
RNA with random decamer primers and a reverse tran-
scriptase enzyme to produce cDNA, amplifying the cDNA 
using HBGv-specific and HSK primers with corresponding 
fluorescently labeled probes, identifying the age of the donor 
55 by determining the cycle threshold (Ct) value of a house-
keeping gene (HSK) and the Ct value of the HBGv target 
gene, then subtracting the Ct value of the target gene, from 
the Ct value of the HSK gene, wherein a positive value 
would indicate that the blood originates from a newborn 
60 human being. 
in certain cases, particularly those involving young children 
such as kidnappings or in providing additional intelligence 65 
during terrorist investigations. Currently no reliable vali-
dated molecular tests are available for age determination. 
A more preferred method uses the reverse transcriptase 
enzyme, Moloney Murine Leukemia Virus (MMLV-RT) and 
has 2 variants of hemoglobin (HBG) used as primers. The 2 
variants ofHBG are HBG ln and HBG2n and the primers are 
segments of HBGln and HBG2n. More preferably, the 
primers are one or more selected from the sequence ID 4, 5, 
6, 7, 8, 9, 10, 11 or 12. 
US 7,276,340 Bl 
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The preferred identifying probes fluoresce and the values 
are determined by finding the Ct of the HSK and the Ct of 
each of the variants of HBG and then subtracting the Ct of 
the HBGv from the Ct of the HSK, generating a dCt value. 
The HSK is the ribosomal protein, S15 and the age of the 5 
newborn is less than 1 week old or the age of the newborn 
can be less than 5 months old. More preferably, the HSK is 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
The life-cycle of humans comprises a number of devel-
opmentally recognized stages. As the human proceeds 
through these developmental stages, sub-sets of the 20-50 
thousand human genes will be differentially expressed. 
Determining the global gene expression profile (or differ-
ential mRNA gene expression profile) present in a biological 
stain could reveal constellations of genes whose expression 
is correlated with a specific age. For example, identifying 
fetal hemoglobin and fetal specific regulating mRNA spe-
cies, isolating pubertal and pre-pubetal hormones and recep-
tors or assaying for DNA damage and repair factors, would 
The preferred extracting procedure for the total RNA uses 
a denaturing solution such as guanidine isothiocyanate- 10 
phenol:chloroform. Preferably, the extracted total RNA is 
precipitated with an organic solvent, such as, isopropanol. 
The preferred enzyme used to treat the extracted total RNA 
be indicative of newborn babies, adolescent teenagers and 
elderly individuals, respectively. 
is deoxyribonuclease I (DNase I). 
A preferred gene coding for the human newborn specific 15 
fetal hemoglobin variant is HBGln as in SEQ ID 1 and 
HBG2n as in SEQ ID 2. 
A clear example of age related differential gene expres-
sion involves the fetal to adult hemoglobin shift. The human 
beta-hemoglobin locus is located on the short arm of chro-
mosome 11 (llp15.5), and encodes five functional beta-like 
globin genes: epsilon, gammaG, ganmiaA, delta, and beta, 
(hemoglobin gamma mRNA sequences, HBGl (gammaA) 
Another preferred gene coding for the human newborn 
specific fetal hemoglobin variants are HBGln and HBG2n 
and polymorphisms thereof. 
A preferred kit for use in determining the biological age 
20 and HBG2 (gammaG), are provided in FIG. 1 and FIG. 2, 
respectively). 
of an individual in an unknown bloodstain, uses HBG ln and 
HBG2n and HSK specific primers, preferably, selected from 
one or more of sequence ID 4, 5, 6, 7, 8, 9, 10, 11, or 12; the 
preferred housekeeping gene is the ribosomal protein, S15. 25 
The preferred probes are labeled with fluorescent dyes. 
The expression of embryonic hemoglobin (epsilon) com-
mences in the yolk sac in the early stages of gestational 
development. During the fifth week of gestation the fetal 
liver, spleen and bone marrow begin to express the fetal 
specific gamma hemoglobin chains (gammaA and gammaG) 
Further objects and advantages of this invention will be 
apparent from the following detailed description and 
example of a presently preferred embodiment. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 provides the mRNA sequence of HBGl 
FIG. 2 provides the mRNA sequence of HBG2 
FIG. 3 provides the mRNA sequence of HBGln 
FIG. 4 provides the mRNA sequence of HBG2n 
FIG. 5 provides the mRNA sequence of S15 
FIG. 6 provides the DNA sequence of an HBGln primer 
FIG. 7 provides the DNA sequences of an HBG 1 n probe 
FIG. 8 provides the DNA sequences of an HBG ln primer 
FIG. 9 provides the DNA sequences of an HBG2n primer 
FIG. 10 provides the DNA sequences of an HBG2n probe 
FIG. 11 provides the DNA sequences of an HBG2n primer 
FIG. 12 provides the DNA sequences of an S15 primer 
FIG. 13 provides the DNA sequences of an S15 probe 
FIG. 14 provides the DNA sequences of an S15 primer 
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
Before explaining the disclosed embodiments of the 
present invention in detail it is to be understood that the 
invention is not limited in its application to the details of the 
particular arrangements shown since the invention is capable 
to form the fetal hemoglobin protein. This up-regulation of 
ganmia-globin is accompanied by a shutdown of epsilon-
globin synthesis. Shortly before birth, beta-globin gene 
30 expression commences in the bone marrow, forming adult 
hemoglobin and inturn ganmia-globin expression is down 
regulated. Therefore, the development of an assay which 
identifies gamma hemoglobin mRNA in a biological stain, 
35 
would indicate that the donor of the stain is a newborn baby. 
The gamma hemoglobin locus was analyzed by reverse 
transcription-polymerase chain reaction (RT-PCR) using 
two sets of highly specific primers, one designed to specifi-
cally amplify HBGl (gammaA) and one designed for ampli-
fication of HBG2 (gammaG). In contrast to our initial 
40 hypothesis, a messenger RNA (mRNA) product correspond-
ing to the individual HBG 1 or HBG2 genes was amplified in 
all age groups tested. These results demonstrated that the 
production of gamma hemoglobin mRNA is not restricted to 
the fetal and newborn stages of development. Upon further 
45 investigation of these RT-PCR assays, the presence of an 
additional lower molecular weight amplimer was detected in 
only newborn individuals. These lower molecular weight 
products were excised, cloned, sequenced and aligned with 
the standard hemoglobin genes. Alignment analysis revealed 
50 these lower molecular weight amplimers to be variants of 
the standard gamma hemoglobin genes (HBGv) which we 
have termed HBGln and HBG2n (variant ganmia hemoglo-
bin mRNA sequences HBGln and HBG2n are provided in 
FIG. 3 and FIG. 4, respectively). 
of other embodiments. Also, the terminology used herein is 55 
for the purpose of description and not of limitation. 
Based on this process the invention provides real-time 
PCR duplexes which are composed of one novel newborn 
specific fetal hemoglobin variant, HBG ln or HBG2n, whose 
sequences are identified as SEQUENCE ID 1 (HBGln) 
(FIG. 3), SEQUENCE ID 2 (HBG2n) (FIG. 4), and one 
Below is a listing of several acronyms used herein: 
DNA is deoxyribonucleic acid 
Ct is cycle threshold value; it is the cycle number at which 
the fluorescent signal passes a pre-determined threshold. 
HBG is hemoglobin 
HSK is housekeeping gene 
RNA is ribonucleic acid 
mRNA is messenger ribonucleic acid 
ROS is reactive oxygen species 
RT-PCR is reverse transcription polymerase chain reaction 
S 15 is ribosomal protein 
60 housekeeping gene (HSK), which may be the ribosomal 
protein, Sl 5, glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) or others (example of a HSK gene sequence, Sl 5, 
(SEQUENCE ID 3) (FIG. 5)). The collection of genes that 
are expressed within the constellation of differentiated cells 
65 that make up a body fluid is called the multicellular tran-
scriptome. These genes comprise ubiquitously expressed 
housekeeping (HSK) genes, which are responsible for cell 
US 7,276,340 Bl 
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maintenance functions independent of biological age, and 
genes that are specifically expressed in an age dependent 
manner. 
Fluorescent (i.e. FAM (6-carboxyfluorescein) and VIC) 
dye-labeled probes (i.e. minor groove binding non-fluores- 5 
cent quencher (MGBNFQ)) and their corresponding unla-
beled primers are incorporated into the real-time PCR 
(qPCR) reaction. These qPCR duplexes have been opti-
mized to determine if a bloodstain originated from a new-
born individual and are sensitive with as little as 50 pg of 10 
input RNA (into the qPCR reaction). The real-time qPCR 
methodology is based on determining the delta cycle thresh-
old (dCt) values generated using the cycle threshold (Ct) of 
the HSK gene and the Ct of the novel hemoglobin variants 
(HBGv) (dCt=Ct S15-Ct HBGv). A positive dCt value 15 
would indicate a newborn origin; in contrast a negative dCt 
value would be obtained with all other ages. 
An mRNA based approach for age determination, such as 
the real time PCR assays described above, could allow the 
facile identification of the newborn specific genes present in 20 
a bloodstain and could rapidly become a validated molecular 
test for newborn specific age determination. 
As an example, the assay of the invention can be per-
formed in two fashions: one in which the newborn is 
identified as less than 1 week old; the other as less than 5 25 
months old, depending on the amount of material used. 
The following example provides further explanation of 
the present invention. 
EXAMPLE 1 30 
For RNA isolation, total RNA is extracted from a blood-
stain using a denaturing solution, composed of guanidine 
isothiocyanate, the RNA is isolated with acid phenol:chlo- 35 
roform and precipitated with isopropanol and GlycoB!ue™ 
glycogen carrier (fromAmbion Inc., Austin, Tex.). The RNA 
is centrifuged and the pellet is washed once with a 75% 
ethanol/25% DEPC-treated water solution. The pellet is 
dried, re-solubilized and stored in an RNAsecure Resuspen-
sion Solution (Ambion Inc., Austin, Tex.). Next, the 40 
extracted total RNA is treated with an enzyme, deoxyribo-
nuclease I (TURBO™ DNase (RNase-Free)) (Ambion Inc., 
Austin, Tex.), quantitated using the unsymmetrical cyanine 
dye RiboGreen® (Molecular Probes, Eugene, Oreg.) and 
then reverse-transcribed using fifty micromolar random 45 
decamers as the first strand primer, producing complemen-
tary DNA (cDNA). The Moloney Murine Leukemia Virus-
Reverse Transcriptase enzyme (MMLV-RT) from Ambion 
Inc., Austin, Tex., was used in this case. Finally, the cDNA 
is amplified using housekeeping and newborn gene-specific 50 
primers (as exemplified in FIGS. 6-14). 
6 
ing the presence of appropriate mRNA species. The gene-
specific primers are incorporated with fluorescently labeled 
probes (i.e. FAM and VIC) into a single multiplexed quan-
titative polymerase chain reaction (qPCR). The mRNA is 
amplified and this amplification is detected by determining 
the fluorescent emission of the dye-labeled probe. 
EXAMPLE 2 
In an assay of the invention which identifies newborns 
that are from 1 hour to 1 week in biological age one may 
proceed as Example 1 above using: 
HBGln 
50 nanomolar of each primer (Forward and Reverse) 
250 nanomolar of the probe 
HBG2n 
50 nanomolar of each primer (Forward and Reverse) 
250 nanomolar of the probe 
S15 
900 nanomolar of each primer (Forward and Reverse) 
250 nanomolar of the probe 
EXAMPLE 3 
In an assay of the invention which identifies newborns 
that are from 1 hour to 5 months in biological age one may 
proceed as in Example I above using: 
HBGln 
100 nanomolar of each primer (Forward and Reverse) 
250 nanomolar of the probe 
HBG2n 
50 nanomolar of each primer (Forward and Reverse) 
250 nanomolar of the probe 
S15 
600 nanomolar of each primer (Forward and Reverse) 
250 nanomolar of the probe 
EXAMPLE 4 
Based on the above extraction and purification technique, 
duplex real-time PCR assays using in this case the Taqman® 
Universal PCR Master Mix in the 7000 Sequence detection 
System from Applied Biosystems, Foster City, Calif., and 
standard cycling conditions such as: Step 1: 1 cycle of 50 
degrees C., for 2:00 minutes; Step 2: 1 cycle of 95 degrees 
C., for 10:00 minutes; Step 3: 40-50 cycles of 95 degrees C., 
for 0: 15 seconds and 60 degrees C., for 1 :00 minute; wherein 
data is collected at stage 3, step 2 (60 degrees C., for 1:00) 
were developed which can definitively identify newborn 
RNA. These duplex reactions are composed of one of the 
two novel variant forms of newborn gamma hemoglobin 
(HBGv), HBGln or HBG2n, and a housekeeping (HSK) 
gene, the ribosomal protein, S15 and have been optimized 
for the detection of newborn individuals from bloodstains. 
The methodology is based on gene expression profiling 
analysis in which the HBGv genes are identified by detect-
The cycle threshold (Ct) values obtained are used to deter-
mine the delta Ct (dCt) for that particular sample. The 
55 equation for dCt calculation is: 
Ct(S 15)-Ct(HBG ln)~dCt 
Ct(S 15)-Ct(HBG2n)~dCt 
60 If the dCt value is positive then the sample originated from 
a newborn. 
If the dCt value is negative then the sample originated from 
an age other than newborn. 
65 If no Ct value is generated with the newborn genes (HBG ln 
or HBG2n) the sample is given a Ct value of 40.000 (the 
maximum number of cycles), for that particular gene. If no 
US 7,276,340 Bl 
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Ct value is generated with the housekeeping gene (S15) than 
the assay must be repeated. 
While the invention has been described, disclosed, illus-
trated and shown in various terms of certain embodiments or 
modifications which it has presumed in practice, the scope 
of the invention is not intended to be, nor should it be 
deemed to be, limited thereby and such other modifications 
or embodiments as may be suggested by the teachings herein 
are particularly reserved especially as they fall within the 
breadth and scope of the claims here appended. 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS: 14 
<210> SEQ ID NO 
<211> LENGTH: 584 
<212> TYPE: DNA 
<213> ORGANISM: HBGl 
<400> SEQUENCE: 
acactcgctt ctggaacgtc tgaggttatc aataagctcc tagtccagac gccatgggtc 60 
atttcacaga ggaggacaag gctactatca caagcctgtg gggcaaggtg aatgtggaag 120 
atgctggagg agaaaccctg ggaaggctcc tggttgtcta cccatggacc cagaggttct 180 
ttgacagctt tggcaacctg tcctctgcct ctgccatcat gggcaacccc aaagtcaagg 240 
cacatggcaa gaaggtgctg acttccttgg gagatgccac aaagcacctg gatgatctca 300 
agggcacctt tgcccagctg agtgaactgc actgtgacaa gctgcatgtg gatcctgaga 360 
acttcaagct cctgggaaat gtgctggtga ccgttttggc aatccatttc ggcaaagaat 420 
tcacccctga ggtgcaggct tcctggcaga agatggtgac tgcagtggcc agtgccctgt 480 
cctccagata ccactgagct cactgcccat gattcagagc tttcaaggat aggctttatt 540 
ctgcaagcaa tacaaataat aaatctattc tgctgagaga tcac 584 
<210> SEQ ID NO 2 
<211> LENGTH: 583 
<212> TYPE: DNA 
<213> ORGANISM: HGB2 
<400> SEQUENCE: 2 
acactcgctt ctggaacgtc tgaggttatc aataagctcc tagtccagac gccatgggtc 60 
atttcacaga ggaggacaag gctactatca caagcctgtg gggcaaggtg aatgtggaag 120 
atgctggagg agaaaccctg ggaaggctcc tggttgtcta cccatggacc cagaggttct 180 
ttgacagctt tggcaacctg tcctctgcct ctgccatcat gggcaacccc aaagtcaagg 240 
cacatggcaa gaaggtgctg acttccttgg gagatgccat aaagcacctg gatgatctca 300 
agggcacctt tgcccagctg agtgaactgc actgtgacaa gctgcatgtg gatcctgaga 360 
acttcaagct cctgggaaat gtgctggtga ccgttttggc aatccatttc ggcaaagaat 420 
tcacccctga ggtgcaggct tcctggcaga agatggtgac tggagtggcc agtgccctgt 480 
cctccagata ccactgagct cactgcccat gatgcagagc tttcaaggat aggctttatt 540 
ctgcaagcaa tcaaataata aatctattct gctaagagat cac 583 
<210> SEQ ID NO 3 
<211> LENGTH: 367 
<212> TYPE: DNA 
<213> ORGANISM: HBGln 
<400> SEQUENCE: 
acactcgctt ctggaacgtc tgaggttatc aataagctcc tagtccagac gccatgggtc 60 
atttcacaga ggaggacaag gctactatca caagcctgtg gggcaaggtg aatgtggaag 120 
atgctggagg agaaaccctg ggaaggctcc tggttgtcta cccatggacc cagaggttct 180 
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ttgacagctt tggcaacctg tcctctgcct ctgccatcat gggcaacccc aaagtcaagg 240 
cacatggcaa gaaggtgctg acttccttgg gagatgccac aaagcacctg gatgattcag 300 
agctttcaag gataggcttt attctgcaag caatacaaat aataaatcta ttctgctgag 360 
agatcac 367 
<210> SEQ ID NO 4 
<211> LENGTH: 421 
<212> TYPE: DNA 
<213> ORGANISM: HBG2n 
<400> SEQUENCE: 
acactcgctt ctggaacgtc tgaggttatc aataagctcc tagtccagac gccatgggtc 60 
atttcacaga ggaggacaag gctactatca caagcctgtg gggcaaggtg aatgtggaag 120 
atgctggagg agaaaccctg ggaaggctcc tggttgtcta cccatggacc cagaggttct 180 
ttgacagctt tggcaacctg tcctctgcct ctgccatcat gggcaacccc aaagtcaagg 240 
cacatggcaa gaaggtgctg acttccttgg gagatgccat aaagcacctg gatgatctca 300 
agggcacctt tgcccagctg agtgaactgc actgagctca ctgcccatga tgcagagctt 360 
tcaaggatag gctttattct gcaagcaatc aaataataaa tctattctgc taagagatca 420 
c 421 
<210> SEQ ID NO 5 
<211> LENGTH: 531 
<212> TYPE: DNA 
<213> ORGANISM: Sl5 
<400> SEQUENCE: 5 
ggcagtctcg cgataactgc gcaggcgcgg accaaagcga tctcttctga ggatccggca 60 
agatggcaga agtagagcag aagaagaagc ggaccttccg caagttcacc taccgcggcg 120 
tggacctcga ccagctgctg gacatgtcct acgagcagct gatgcagctg tacagtgcgc 180 
gccagcggcg gcggctgaac cggggcctgc ggcggaagca gcactccctg ctgaagcgcc 240 
tgcgcaaggc caagaaggag gcgccgccca tggagaagcc ggaagtggtg aagacgcacc 300 
tgcgggacat gatcatccta cccgagatgg tgggcagcat ggtgggcgtc tacaacggca 360 
agaccttcaa ccaggtggag atcaagcccg agatgatcgg ccactacctg ggcgagttct 420 
ccatcaccta caagcccgta aagcatggcc ggcccggcat cggggccacc cactcctccc 480 
gcttcatccc tctcaagtaa tggctcagct aataaaggcg cacatgactc c 531 
<210> SEQ ID NO 6 
<211> LENGTH: 23 
<212> TYPE: DNA 
<213> ORGANISM: HBGln 
<400> SEQUENCE: 
gaaagctctg aatcatccag gtg 23 
<210> SEQ ID NO 7 
<211> LENGTH: 27 
<212> TYPE: DNA 
<213> ORGANISM: HBGln 
<400> SEQUENCE: 
tttgtggcat ctcccaagga agtcagc 27 
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<210> SEQ ID NO 8 
<211> LENGTH: 22 
<212> TYPE: DNA 
<213> ORGANISM: HBGln 
<400> SEQUENCE: 
agtcaaggca catggcaaga ag 
<210> SEQ ID NO 9 
<211> LENGTH: 21 
<212> TYPE: DNA 
<213> ORGANISM: HBG2n 
<400> SEQUENCE: 
gcagtgagct cagtgcagtt c 
<210> SEQ ID NO 10 
<211> LENGTH: 26 
<212> TYPE: DNA 
<213> ORGANISM: HBG2n 
<400> SEQUENCE: 10 
caaaggtgcc cttgagatca tccagg 
<210> SEQ ID NO 11 
<211> LENGTH: 21 
<212> TYPE: DNA 
<213> ORGANISM: HBG2n 
<400> SEQUENCE: 11 
ttccttggga gatgccataa a 
<210> SEQ ID NO 12 
<211> LENGTH: 23 
<212> TYPE: DNA 
<213> ORGANISM: SlS 
<400> SEQUENCE: 12 
ccaaagcgat ctcttctgag 
<210> SEQ ID NO 13 
<211> LENGTH: 27 
<212> TYPE: DNA 
<213> ORGANISM: SlS 
<400> SEQUENCE: 13 
gat 
cggcaagatg gcagaagtag agcagaa 
<210> SEQ ID NO 14 
<211> LENGTH: 17 
<212> TYPE: DNA 
<213> ORGANISM: SlS 
<400> SEQUENCE: 14 
acgccgcggt aggtgaa 
We claim: 
1. A method for identifying whether a stain contains blood 
of a newborn human being, comprising the steps of: 
a) obtaining a sample stain comprising blood from a 
human being; 
b) extracting total ribonucleic acid (tRNA) from the 
sample stain; 
60 
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c) treating the total RNA with an enzyme; 
d) initiating a reverse-transcription (RT) reaction by treat-
ing total RNA with random decamer primers and a 
reverse transcriptase enzyme to produce cDNA; 
e) amplifying the cDNA using HBGv-specific primers 
consisting of SEQ ID NO: 9 and SEQ ID NO: 7 and 
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HSK primers with corresponding fluorescently labeled 
probes; 
f) identifying the age of the donor by determining the 
cycle threshold (Ct) value of a housekeeping gene 
(HSK) and the Ct value of the HBGv target gene, then 5 
subtracting the Ct value of the target gene, from the Ct 
value of the HSK gene, wherein a positive value would 
indicate that the blood originates from a newborn 
human being. 
2. The method, as in claim 1, wherein the reverse tran- 10 
scriptase enzyme is Moloney Murine Leukemia Virus 
(MMLV-RT). 
3. A method, as in claim 1, wherein 2 variants of hemo-
globin (HBG) are used as primers. 
4. A method, as in claim 3, wherein the 2 variants ofHBG 15 
are HBGln and HBG2n. 
5. A method, as in claim 4 wherein the primers are 
segments ofHBGln and HBG2n. 
6. A method, as in claim 5 wherein the primers are one or 
more selected from the group consisting of sequence ID 4, 20 
5, 6, 7, 8, 9, 10, 11 and 12. 
7. A method, as in claim 5 wherein the identifying probes 
fluoresce and the values are determined by finding the Ct of 
the HSK and the Ct of each of the variants of HBG and then 
14 
subtracting the Ct of the HBGv from the Ct of the HSK, 
generating a dCt value. 
8. A method, as in claim 5, wherein the HSK is the 
ribosomal protein, S15. 
9. A method, as in claim 5, wherein the age of the newborn 
is less than 1 week old. 
10. A method, as in claim 5, wherein the age of the 
newborn is less than 5 months old. 
11. A method, as in claim 5, wherein the HSK is glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH). 
12. The method of claim 1, wherein the total RNA is 
extracted with a denaturing solution. 
13. The method of claim 1, wherein the extracting pro-
cedure is guanidine isothiocyanate-phenol:chloroform. 
14. The method of claim 1, wherein the extracted total 
RNA is precipitated with an organic solvent. 
15. The method of claim 1, wherein the organic solvent is 
isopropanol. 
16. The method of claim 1, wherein the enzyme used to 
treat the extracted total RNA is deoxyribonuclease I (DNase 
I). 
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